Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab

Official title

Long-course Concurrent Chemoradiotherapy Combined With Camrelizumab in the Neoadjuvant Treatment of Locally Advanced/Low Anus-preserving Rectal Cancer: a Phase II Single-arm Study.

Overview

This is a single-arm, phase II clinical study aim to evaluate the efficacy and safety of long-term concurrent chemoradiotherapy combined with camrelizumab as a neoadjuvant therapy in the treatment of locally advanced/low rectal cancer requiring anus preservation.

Detailed description

This study plans to recruit 48 patients with locally advanced/low anal preservation requiring rectal cancer. The study aims to observe and evaluate the efficacy and safety of long-term concurrent chemoradiotherapy combined with camrelizumab.

Interventions

• Drug Camrelizumab
  Camrelizumab IV 200mg
• Drug Chemotherapy
  Capecitabine PO oxaliplatin IV
• Radiation Radiotherapy
  Radiotherapy 50Gy /45Gy /25 fractions

Primary outcome measures

• Pathological Complete Response rate [Time frame: up to 24 months]

Secondary outcome measures (7)

• Objective Response Rate [Time frame: up to 24 months]
• Disease Control Rate [Time frame: up to 24 months]
• Anal preservation rate [Time frame: up to 24 months]
• Disease-free Survival [Time frame: up to 24 months]
• Overall Survival [Time frame: up to 36 months]
• AEs [Time frame: up to 24 months]
• 3-years Overall Survival rate [Time frame: up to 36 months]

Eligibility criteria

Inclusion criteria

• Age: 18 to 75 years old, male or female,
• Histologically or cytologically confirmed rectal cancer with measurable tumour lesions (Spiral CT or MR scans ≥ 10 mm, meeting RECIST 1.1 criteria),
• Clinical stage: Rectal cancer cT3-4N0M0 or cT1-4N+M0 and low rectal cancer with need for anal preservation (<5 cm from anal verge; T2N0M0),
• Expected survival > 3 months,
• ECOG PS score: 0-1,
• No peritoneal metastasis or other distant metastasis; Note: the presence of distant metastasis should be confirmed by CT or MR scan. If bone metastasis is suspected, a bone scan should be performed. If peritoneal metastasis is suspected, PET-CT should be performed or laparoscopy should be performed. If brain metastases are suspected, CT or MR should be performed,
• No previous radiotherapy or immune checkpoint inhibitor treatment for rectal cancer,
• Function of vital organs in accordance with the following requirements (excluding the use of any blood components and cell growth factors during screening):

1)Absolute neutrophil count ≥ 1.5 x 10\^9/L; platelets ≥ 80 x 10\^9/L; hemoglobin ≥ 8.5 g/dL, 2)Thyroid-stimulating hormone (TSH) ≤1 times ULN (if abnormal, T3 and T4 levels should be examined at the same time; if T3 and T4 levels are normal, they can be enrolled), 3)Bilirubin ≤1.5 times ULN; ALT and AST ≤2.5 times ULN, 4) Serum creatinine ≤1.5 times ULN, 9. Women of childbearing potential must undergo a negative pregnancy test (βHCG) prior to initiation of treatment, and women of childbearing potential and men who are sexually active with women of childbearing potential must agree to use effective contraception uninterruptedly for the duration of the treatment period and for 6 months after the administration of the last therapeutic dose, 10. Subjects voluntarily enrolled in the study and signed an informed consent form.

Exclusion criteria

• Previous pelvic or abdominal radiotherapy,
• Tumours that are expected to be unresectable after neoadjuvant therapy,
• Pregnant or lactating women, or those of childbearing potential who refuse to use contraception,
• History of other malignancies within the past 5 years, except adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or basal cell carcinoma of the skin that has been substantially controlled,
• Ineffectively controlled, symptomatic brain metastases or a history of psychosis that cannot be easily controlled or severe intellectual or cognitive dysfunction,
• Pulmonary fibrosis, interstitial pneumonitis, pneumoconiosis, radiation pneumonitis, drug-associated pneumonitis and severely impaired lung function,
• Subjects with active, known or suspected autoimmune disease, hypothyroidism requiring only hormone replacement therapy, skin disorders that do not require systemic therapy (e.g., vitiligo, psoriasis, or alopecia areata) may be eligible for enrolment,
• Congestive heart failure, difficult-to-control cardiac arrhythmia, myocardial infarction within 6 months, unstable angina, stroke or transient is chaemic attack, severe hypertension difficult to control with medication, or other patients who cannot tolerate the procedure,
• Severe active infections requiring intravenous antibiotic treatment occurring during the screening period,
• Allergy to the test drug,
• Have received or will receive a live vaccine within 30 days prior to camrelizumab administration,
• Known history of HIV infection or active hepatitis B or C,
• Patients who are unable to comply with the trial protocol or are unable to cooperate with follow-up visits,
• Those who in the opinion of the investigator are not suitable for participation in this trial.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06304545 · SHR-1210-HLJ-081

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗